Tags

Type your tag names separated by a space and hit enter

Diagnosis and treatment of gastric neuroendocrine tumours.
Wien Klin Wochenschr. 2007; 119(19-20):570-2.WK

Abstract

Gastric neuroendocrine tumours (NET) are rare. Clinically they are classified in tumours type 1 to 3. The histological classification is according to the WHO 2000 classification for endocrine tumours. NET type 1 occur in coincidence with chronic atrophic gastritis, as single or multiple small tumours. The prognosis of type 1 tumours is excellent, with no tumour related death reported during follow-up. NET type 2 are part of the MEN-1 syndrome. These tumours may be more aggressive and even develop metastasis. However, in most patients with MEN-1 the prognosis is due to other manifestations of the disease as duodenal or pancreatic neuroendocrine tumours. Gastric neuroendocrine tumours type 3 are sporadic tumours without relationship to other gastric pathology. They tend to occur earlier, without sex preference. These tumours may develop an aggressive course, with metastatic disease and an overall poor prognosis. Thus, aggressive surgical therapy is recommended.

Authors+Show Affiliations

Interdisziplinäres Stoffwechsel-Centrum: Endokrinologie, Diabetes und Stoffwechsel, Charité-Universitätsmedizin Berlin, Berlin, Germany. Ursula.ploeckinger@charite.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17985089

Citation

Plöckinger, Ursula. "Diagnosis and Treatment of Gastric Neuroendocrine Tumours." Wiener Klinische Wochenschrift, vol. 119, no. 19-20, 2007, pp. 570-2.
Plöckinger U. Diagnosis and treatment of gastric neuroendocrine tumours. Wien Klin Wochenschr. 2007;119(19-20):570-2.
Plöckinger, U. (2007). Diagnosis and treatment of gastric neuroendocrine tumours. Wiener Klinische Wochenschrift, 119(19-20), 570-2.
Plöckinger U. Diagnosis and Treatment of Gastric Neuroendocrine Tumours. Wien Klin Wochenschr. 2007;119(19-20):570-2. PubMed PMID: 17985089.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnosis and treatment of gastric neuroendocrine tumours. A1 - Plöckinger,Ursula, PY - 2007/11/7/pubmed PY - 2008/3/5/medline PY - 2007/11/7/entrez SP - 570 EP - 2 JF - Wiener klinische Wochenschrift JO - Wien Klin Wochenschr VL - 119 IS - 19-20 N2 - Gastric neuroendocrine tumours (NET) are rare. Clinically they are classified in tumours type 1 to 3. The histological classification is according to the WHO 2000 classification for endocrine tumours. NET type 1 occur in coincidence with chronic atrophic gastritis, as single or multiple small tumours. The prognosis of type 1 tumours is excellent, with no tumour related death reported during follow-up. NET type 2 are part of the MEN-1 syndrome. These tumours may be more aggressive and even develop metastasis. However, in most patients with MEN-1 the prognosis is due to other manifestations of the disease as duodenal or pancreatic neuroendocrine tumours. Gastric neuroendocrine tumours type 3 are sporadic tumours without relationship to other gastric pathology. They tend to occur earlier, without sex preference. These tumours may develop an aggressive course, with metastatic disease and an overall poor prognosis. Thus, aggressive surgical therapy is recommended. SN - 0043-5325 UR - https://www.unboundmedicine.com/medline/citation/17985089/Diagnosis_and_treatment_of_gastric_neuroendocrine_tumours_ L2 - https://dx.doi.org/10.1007/s00508-007-0879-z DB - PRIME DP - Unbound Medicine ER -